ArticleGastroenterology research2026
Trends and Impact of
Article in Gastroenterology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: This retrospective analysis used the Nationwide Readmissions Database from 2016 to 2022. Patients undergoing CABG were identified using International Classification of Diseases, 10th Revision (ICD-10) procedure codes. Patients with CDI were identified using ICD-10 diagnosis codes. Multiple logistic regression was performed to adjust for confounding factors. Trend analysis was done. Results: A total of 1,279,605 adult patients undergoing CABG were included, of whom 5,567 (0.44%) had concurrent CDI. Patients with CDI were older (mean age 68.6 vs. 66.3 years, P < 0.001) and had higher medical comorbidity (Charlson Comorbidity Index ≥ 3: 68.4% vs. 45.35%, P < 0.001). They also had significantly higher rates of 30-day readmissions (12.63% vs. 7.35%, adjusted odds ratio (aOR), 1.42), in-hospital mortality (11.64% vs. 2.58%, aOR, 2.72), and complications including cardiac arrest (7.56% vs. 2.04%, aOR, 2.55), cardiogenic shock (26.89% vs. 9.50%, aOR, 2.33), sepsis/septic shock (26.05% vs. 2.51%, aOR, 8.28), all with P < 0.001. Over the study period, there was a decline in CABG admissions. CDI incidence among CABG patients also declined with a parallel decline in 30-day readmissions. Conclusions: Patients who underwent CABG with concurrent CDI experienced greater readmission rates, mortality, periprocedural adverse events, and resource utilization. Further studies need to be done for possible interventions to reduce these outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.